OrbusNeich Medical Group Holdings Limited
業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board is pleased to announce the interim condensed consolidated results of the Group for the six months ended June 30, 2025, together with the comparative figures for the six months ended June 30, 2024.

FINANCIAL HIGHLIGHTS

	For the six months ended June 30,		
	2025	2024	**Change**
	US$'000	*US$'000*	
	(Unaudited)	(Unaudited)	
Operating results			
Revenue	**83,550**	78,910	5.9%
Cost of sales	**(27,653)**	(23,134)	19.5%
Gross profit	**55,897**	55,776	0.2%
Profit before income tax	**20,775**	21,285	−2.4%
Profit for the period attributable to owners of the Company	**19,785**	18,828	5.1%
Basic earnings per share *(US cents)*	**2.40**	2.28	5.3%
Diluted earnings per share *(US cents)*	**2.40**	2.28	5.3%
Profitability			
Gross profit margin[(1)]	**66.9%**	70.7%	−3.8% points
Net profit margin[(2)]	**23.7%**	23.9%	−0.2% points

Notes:

(1) Calculated by dividing gross profit by revenue.

(2) Calculated by dividing profit for the period attributable to owners of the Company by revenue.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2025

	Note	Six months ended June 30, 2025 **US$'000** **(Unaudited)**	2024 US$'000 (Unaudited)
Revenue	3	**83,550**	78,910
Cost of sales	6	**(27,653)**	(23,134)
Gross profit		**55,897**	55,776
Other income — net	4	**117**	169
Other gains/(losses) — net	5	**1,099**	(897)
Selling and distribution expenses	6	**(19,632)**	(18,510)
General and administrative expenses	6	**(12,025)**	(12,903)
Research and development expenses	6	**(8,074)**	(7,398)
Net impairment losses on financial assets		**(549)**	(366)
Operating profit		**16,833**	15,871
Finance income		**4,856**	6,199
Finance costs		**(112)**	(126)
Finance income — net		**4,744**	6,073
Share of loss of investment in a joint venture		**(802)**	(659)
Profit before income tax		**20,775**	21,285
Income tax expense	7	**(929)**	(2,412)
Profit for the period		**19,846**	18,873
Profit for the period attributable to			
Owners of the Company		**19,785**	18,828
Non-controlling interests		**61**	45
		19,846	18,873
Earnings per share	9	***US cents***	*US cents*
Basic		**2.40**	2.28
Diluted		**2.40**	2.28

The above interim condensed consolidated statement of profit or loss should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2025

	Note	Six months ended June 30, 2025 **US$'000** **(Unaudited)**	2024 *US$'000* (Unaudited)
Profit for the period		**19,846**	18,873
Other comprehensive income/(loss):			
Item that will not be subsequently reclassified to profit or loss			
Remeasurements of post-employment benefit obligations		**(219)**	53
Items that may be subsequently reclassified to profit or loss			
Currency translation differences		**6,008**	(4,055)
Other comprehensive income/(loss) for the period, net of tax		**5,789**	(4,002)
Total comprehensive income for the period		**25,635**	14,871
Total comprehensive income for the period attributable to			
Owners of the Company		**25,577**	14,887
Non-controlling interests		**58**	(16)
		25,635	14,871

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

As at June 30, 2025

	Note	**June 30, 2025** ***US$'000*** **(Unaudited)**	December 31, 2024 *US$'000* (Audited)
ASSETS			
Non-current assets			
Property, plant and equipment		**29,136**	21,197
Right-of-use assets		**6,575**	6,404
Deferred income tax assets		**7,642**	5,307
Financial assets at fair value through profit or loss		**1,130**	1,300
Intangible assets		**10,486**	9,755
Goodwill		**11,145**	10,205
Interest in a joint venture		**14,111**	13,613
Deposits and prepayments		**2,318**	1,772
Total non-current assets		**82,543**	69,553
Current assets			
Inventories		**67,228**	56,329
Trade receivables	*10*	**44,670**	41,679
Deposits, prepayments and other receivables		**11,448**	12,180
Amounts due from joint ventures		**2,114**	1,595
Tax recoverable		**659**	1,084
Cash and bank balances		**237,140**	248,590
Total current assets		**363,259**	361,457
Total assets		**445,802**	431,010
EQUITY			
Capital and reserves attributable to owners of the Company			
Share capital		**414**	414
Other reserves		**427,426**	431,652
Accumulated losses		**(18,983)**	(38,757)
		408,857	393,309
Non-controlling interests		**1,126**	1,068
Total equity		**409,983**	394,377

	Note	**June 30, 2025** ***US$'000*** **(Unaudited)**	December 31, 2024 *US$'000* (Audited)
LIABILITIES			
Non-current liabilities			
Lease liabilities		**2,134**	2,417
Retirement benefit obligations		**3,073**	2,623
Deferred income tax liabilities		**865**	870
Total non-current liabilities		**6,072**	5,910
Current liabilities			
Trade payables	*11*	**5,249**	6,840
Accruals and other payables		**18,266**	19,720
Financial liability at fair value through profit or loss		**500**	—
Amount due to a joint venture		**—**	58
Current income tax liabilities		**3,434**	2,321
Lease liabilities		**2,298**	1,784
Total current liabilities		**29,747**	30,723
Total liabilities		**35,819**	36,633
Total equity and liabilities		**445,802**	431,010

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1 GENERAL INFORMATION

OrbusNeich Medical Group Holdings Limited (the "**Company**") is a limited liability company incorporated and domiciled in the Cayman Islands. The address of its registered office is Conyers Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY1-1111, Cayman Islands.

The Company is an investment holding company. The Company and its subsidiaries (collectively, the "**Group**"), are principally engaged in the manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases.

The immediate and ultimate holding company is Harmony Tree Limited, a company incorporated in the British Virgin Islands with limited liability. The ultimate controlling shareholders of the Group are Mr. David CHIEN and Ms. Kwai Ching Denise LAU, spouse of Mr. David CHIEN (the "**Controlling Shareholders**").

The unaudited interim condensed consolidated financial information is presented in thousands of United State Dollar ("**US$'000**"), unless otherwise stated.

2 BASIS OF PREPARATION

This interim condensed consolidated financial information for the six months ended June 30, 2025 has been prepared in accordance with Hong Kong Accounting Standard ("**HKAS**") 34, "Interim Financial Reporting". The interim condensed consolidated financial information should be read in conjunction with the annual financial statements for the year ended December 31, 2024, which have been prepared in accordance with Hong Kong Financial Reporting Standards ("**HKFRSs**").

The unaudited interim condensed consolidated financial information has been prepared under historical cost convention, except for financial assets and liabilities at fair value through profit or loss or other comprehensive income, which are carried at fair value.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

2.1 Amendments to standards adopted by the Group

The Group has applied the following amendments to standards, for the first time for their annual reporting period commencing on January 1, 2025:

Amendments to HKAS 21	Lack of Exchangeability

The amendments listed above did not have any material impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods.

2.2 New and amendments to standards not yet adopted by the Group

Certain new standards and amendments to standards have been published that are not mandatory for the financial year beginning January 1, 2025 and have not been early adopted by the Group in preparing the interim condensed consolidated financial information:

		Effective for accounting year beginning on or after
Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments	January 1, 2026
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature — dependent Electricity	January 1, 2026
Annual Improvements	Annual Improvements to HKFRS Accounting Standards — Volume 11	January 1, 2026
HKFRS 18	Presentation and Disclosure in Financial Statements	January 1, 2027
HKFRS 19	Subsidiaries without Public Accountability: Disclosures	January 1, 2027
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

The Group will adopt the above new and amendments to standards as and when they become effective. The directors of the Company have performed preliminary assessment and do not anticipate any significant impact on the Group's financial position and results of operations upon adopting these amendments to accounting standards and interpretation to existing HKFRS.

3 REVENUE AND SEGMENT INFORMATION

The chief operating decision-maker ("**CODM**") considers the business from a product perspective which is manufacturing, trading, sales and marketing of medical devices/instruments used for the treatment of coronary and peripheral vascular diseases. The CODM regularly reviews the financial information of the Group which is the same as the consolidated financial statements of the Group, for the purposes of allocating resources and assessing its performance, so only one operating segment of the Group and, no separate segmental analysis is presented in the interim condensed consolidated financial information.

The amounts provided to the CODM with respect to total assets and total liabilities are measured in a manner consistent with that in the interim condensed consolidated balance sheet.

The revenue recognized during the period are as follows:

	Six months ended June 30,	
	2025	2024
	US$'000	*US$'000*
	(Unaudited)	(Unaudited)
Sales of goods — at point in time	**83,550**	78,910

Geographical information

The Group is organized on a worldwide basis. The analysis of revenue by geographical area is as follows:

	Asia Pacific region, except Japan and the PRC ("APAC") *US$'000*	**Europe, Middle East & Africa ("EMEA")** *US$'000*	**Japan** *US$'000*	**The PRC** *US$'000*	**United States** *US$'000*	**Total** *US$'000*
Six months ended June 30, 2025 (Unaudited)						
Revenue	**73,396**	**45,795**	**16,114**	**35,590**	**8,044**	**178,939**
Less: inter-segment revenue	**(46,085)**	**(23,366)**	**—**	**(25,938)**	**—**	**(95,389)**
Revenue from external customers	**27,311**	**22,429**	**16,114**	**9,652**	**8,044**	**83,550**
Six months ended June 30, 2024 (Unaudited)						
Revenue	61,597	35,501	18,908	31,468	6,701	154,175
Less: inter-segment revenue	(37,642)	(16,331)	—	(21,292)	—	(75,265)
Revenue from external customers	23,955	19,170	18,908	10,176	6,701	78,910

The non-current assets information below is based on the location of assets other than financial instruments and deferred income tax assets.

	As at June 30, 2025 ***US$'000*** **(Unaudited)**	As at December 31, 2024 *US$'000* (Audited)
APAC	**33,674**	31,000
EMEA	**6,957**	6,237
Japan	**773**	757
The PRC	**29,328**	21,953
United States	**2,006**	2,243
	72,738	62,190

4 OTHER INCOME — NET

	Six months ended June 30,	
	2025	2024
	US$'000	*US$'000*
	(Unaudited)	(Unaudited)
Government grants *(Note)*	**82**	177
Others	**35**	(8)
	117	169

Note: Government grants mainly comprise subsidies received from various local governments in the PRC. There were no unfulfilled conditions and other contingencies attached to the receipts of those grants.

5 OTHER GAINS/(LOSSES) — NET

	Six months ended June 30,	
	2025	2024
	US$'000	*US$'000*
	(Unaudited)	(Unaudited)
Net foreign exchange gains/(losses)	**1,507**	(746)
Fair value changes in financial assets at fair value through profit or loss	**(391)**	(156)
Others	**(17)**	5
	1,099	(897)

6 EXPENSES BY NATURE

	Six months ended June 30,	
	2025	2024
	US$'000	*US$'000*
	(Unaudited)	(Unaudited)
Cost of inventories recognized as expense (including write-down of inventories to net realizable value)	**14,857**	12,288
Employee benefit expenses	**30,959**	29,043
Depreciation of property, plant and equipment	**1,212**	1,003
Depreciation of right-of-use assets	**1,074**	1,029
Amortization of intangible assets	**600**	583
Short-term lease expense in respect of office premises	**730**	676
Royalty expenses	**1,832**	1,730
Auditors' remuneration	**239**	239
Marketing and advertising expenses	**2,408**	3,018
Legal and professional fees	**986**	1,508
Clinical trial expenses	**24**	725
Travel and entertainment expenses	**2,570**	2,031
Testing material expenses	**1,310**	997
Commission expenses	**360**	766
Delivery and warehouse charge	**1,687**	1,327
Transportation expenses	**362**	198
Telecommunication expenses	**141**	153
Insurance expenses	**588**	817
Other expenses	**5,445**	3,814
	67,384	61,945

7 INCOME TAX EXPENSE

	Six months ended June 30,	
	2025	2024
	US$'000	*US$'000*
	(Unaudited)	(Unaudited)
Current income tax:		
Current income tax on profits for the period	**3,303**	1,942
Under-provision in prior periods	**19**	161
	3,322	2,103
Deferred income tax:		
Relating to the origination and reversal of temporary differences	**(2,393)**	309
	929	2,412

The Group is primarily subject to the Hong Kong profits tax, PRC corporate income tax ("**CIT**"), Japan corporate income tax, the Netherlands corporate income tax, Indonesia corporate income tax and the United States corporate income tax.

(a) Hong Kong profits tax

The applicable profits tax rate in Hong Kong is 16.5% for the six months ended June 30, 2025 (for the six months ended June 30, 2024: 16.5%).

(b) PRC corporate income tax

OrbusNeich Medical (Shenzhen) Company Limited ("**OrbusNeich Shenzhen**") was qualified as a National High and New Technology Enterprise ("**HNTE**"), on December 25, 2023 with a validity of three years therefrom. According to the CIT Law, the enterprise qualifying the HNTE status is entitled to the 15% reduced CIT rate subject to a record-filing to the in-charge tax bureau. OrbusNeich Shenzhen had completed the record-filing with Shenzhen local tax bureau. As such, the applicable CIT rate is 15% for the six months ended June 30, 2025 (for the six months ended June 30, 2024: 15%).

(c) Japan corporate income tax

The applicable corporate income tax in Japan is 33.58% for the six months ended June 30, 2025 (for the six months ended June 30, 2024: 33.58%).

(d) The Netherlands corporate income tax

For the six months ended June 30, 2025, Netherlands corporate income tax has been provided for at the rate of 25.8% on the estimated assessable profits of Netherlands subsidiaries (for the six months ended June 30, 2024: 25.8%).

(e) Indonesia corporate income tax

For the six months ended June 30, 2025, the Indonesia corporate income tax rate has been provided for at the rate of 22.0% on the estimated assessable profit of the Indonesian subsidiary (for the six months ended June 30, 2024: 22.0%).

(f) The United States corporate income tax

The applicable federal corporate income tax in the United States is 21% and state income tax in the United States is 5.5% for the six months ended June 30, 2025 (for the six months ended June 30, 2024: 21% and 5.5%).

8 DIVIDEND

(a) Final dividend

A final dividend in respect of the year ended December 31, 2024 of HK10 cents per share (approximately US1.28 cents) (2023: HK10 cents (approximately US1.28 cents) was proposed pursuant to a resolution passed by the Board and approved by the shareholders at the 2025 annual general meeting of the Company held on May 27, 2025. Such dividend amounted to US$10,610,000 (2024: US$10,615,000) was paid during the six months ended June 30, 2025.

(b) Interim dividend

No interim dividend has been declared and paid by the Company for the six months ended June 30, 2025 and 2024.

(c) Special dividend

On August 15, 2025, the Company has resolved to declare a special dividend of HK15 cents (approximately US1.92 cents) per share, approximately amounting to a total of HK$124,195,000 (approximately US$15,922,000). These financial statements do not reflect this dividend payable.

9 EARNINGS PER SHARE

(a) Basic earnings per share

The basic earnings per share is calculated based on the profit attributable to owners of the Company for the six months ended June 30, 2025 divided by the weighted average number of shares in issue during the period (2024: Same).

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited)
Profit attributable to owners of the Company *(US$'000)*	**19,785**	18,828
Weighted average number of ordinary shares in issue *(thousand shares)*	**823,813**	826,601
Basic earnings per share *(US cents)*	**2.40**	2.28

The weighted average number of ordinary shares in issue used for the calculation of basic earnings per share for the six months ended June 30, 2025 has excluded shares held for employee share award schemes during the six months ended June 30, 2025.

(b) Diluted earnings per share

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the six months ended June 30, 2025 and 2024, the Company had outstanding share options and share awards that are potential ordinary shares.

Diluted earnings per share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the respective period as follows:

	Six months ended June 30,	
	2025	2024
	(Unaudited)	(Unaudited)
Profit attributable to owners of the Company *(US$'000)*	**19,785**	18,828
Weighted average number of ordinary shares in issue *(thousand shares)*	**823,813**	826,601
Weighted average number of share options *(thousand shares)*	**—**	6
Weighted average number of share awards *(thousand shares)*	**1,245**	—
Weighted average number of ordinary shares for diluted earnings per share *(thousand shares)*	**825,058**	826,607
Diluted earnings per share *(US cents)*	**2.40**	2.28

10 TRADE RECEIVABLES

	As at June 30, 2025	As at December 31, 2024
	US$'000	*US$'000*
	(Unaudited)	(Audited)
Trade receivables *(Note)*	**46,272**	42,687
Loss allowance	**(1,602)**	(1,008)
Trade receivables, net	**44,670**	41,679

Note: The majority of the Group's sales are with credit terms of 30 to 180 days. The carrying amounts of trade receivables approximate their fair values.

The ageing analysis of the trade receivables based on invoice date, before provision for impairment, is as follows:

	As at June 30, 2025	As at December 31, 2024
	US$'000	*US$'000*
	(Unaudited)	(Audited)
0 to 30 days	**24,273**	23,485
31 to 60 days	**6,903**	7,542
61 to 90 days	**5,710**	4,753
Over 90 days	**9,386**	6,907
	46,272	42,687

The Group applies the HKFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

11 TRADE PAYABLES

	As at June 30, 2025	As at December 31, 2024
	US$'000	*US$'000*
	(Unaudited)	(Audited)
Trade payables	**5,249**	6,840

The carrying amounts of trade payables approximate their fair values.

Credit terms granted by creditors generally range from 30 to 90 days.

The ageing analysis of the trade payables based on invoice date is as follows:

	As at June 30, 2025	As at December 31, 2024
	US$'000	*US$'000*
	(Unaudited)	(Audited)
0 to 30 days	**3,240**	2,772
31 to 60 days	**921**	1,664
61 to 90 days	**592**	1,360
Over 90 days	**496**	1,044
	5,249	6,840

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

Introduction

OrbusNeich is a multinational medical device company specializing in interventional devices for PCI and PTA procedures. Headquartered in Hong Kong, China, the Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, the Group has developed world-leading proprietary technologies.

The Group's diversified product portfolio covers all major treatment processes in PCI and PTA procedures. The approved and marketed products are indicated for lesion access, lesion preparation, lesion therapy and lesion optimization, encompassing semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, drug-coated balloons and stents for lesion therapy, non-compliant balloons for post-dilatation, and specialty catheters.

Overall Performance in the First Half of 2025

In the first half of 2025, the macroeconomic landscape and geopolitical situation presented significant challenges to the Group. Heightened trade protectionism created uncertainties that impacted the growth momentum in the US market, while also testing our global supply chain capabilities in effectively navigating international markets. Nevertheless, we achieved strong year-on-year growth in the US market despite tariff disruptions, demonstrating robust demand for the Group's quality products. Moreover, we have observed positive trends driven by continuous socioeconomic development in certain emerging markets, particularly in the APAC and EMEA regions, which were the key growth drivers in the first half of the year. However, this growth was partly offset by a decline in sales volume in the Japanese market and a decrease in the average selling price in the PRC market. For the six months ended June 30, 2025, the Group recorded revenue of US$83.6 million, representing an increase of 5.9% as compared with the corresponding period last year. Sales volume during the Reporting Period reached 919,000 units, of which 779,000 units were proprietary products, representing an increase of 8.6% year-on-year. Gross profit was approximately US$55.9 million which remained flat as compared to the corresponding period of last year.

Profit attributable to owners of the Company in the first half of 2025 amounted to US$19.8 million, representing an increase of 5.1% year-on-year. Basic earnings per share for the first half of 2025 was US2.40 cents (first half of 2024: US2.28 cents). Core operating profit, being profit attributable to owners of the Company, excluding share-based compensation expenses, net tax credit from deferred tax asset in relation to tax losses and finance income/costs, amounted to US$15.1 million, up by 11.4% year-on-year. 2025 marks the 25th anniversary of the Group. In appreciation of the long-standing support from Shareholders, the Board has resolved to declare a special dividend of HK15 cents per ordinary share in cash. Together with the final dividend of HK10 cents per ordinary share for the year ended December 31, 2024 paid on June 16, 2025, Shareholders will receive a total dividend of HK25 cents in 2025.

Performance by Geographical Market

APAC

In the first half of 2025, revenue from the APAC market continued to rise significantly, climbing to US$27.3 million and achieving year-on-year growth of 14.0%. The Indonesian market achieved exceptional progress, with both proprietary and third-party products witnessing impressive growth. Additionally, the increasing adoption of Scoreflex TRIO in Singapore and Malaysia has contributed considerably to the revenue growth.

EMEA

In the first half of 2025, revenue generated from EMEA significantly increased by 17.0% to US$22.4 million. The increase was mainly attributable to the rise in sales of the Group's proprietary balloon products in direct sales markets such as Germany, France and Spain, as well as distributor sales markets including the United Kingdom, Slovakia and the Czech Republic.

Japan

During the first half of 2025, the revenue from Japan declined by 14.8% year-on-year to US$16.1 million. This was mainly due to the decrease in sales volume after shifting the sales strategy to focus less on products with lower selling prices, including certain coronary balloons. Despite a decline in revenue in the Japanese market in the first half of the year, a significant reduction in sales and marketing expenses for this market effectively mitigated the impact of the revenue decline on profitability.

The PRC

Following the gradual implementation of the Hebei-Beijing-Tianjin 3+N volume-based procurement ("**VBP**") program in mid-2024, the product mix in the PRC market saw a shift towards a higher proportion of VBP products. In particular, the sales volume of standard balloons, including Sapphire II PRO, Sapphire 3, and Sapphire II NC, increased in the first half of 2025. However, due to the decline in the average selling price resulting from the increased sale of VBP products, revenue from the PRC decreased by 5.1% year-on-year to US$9.7 million for the first half of 2025.

The US

Despite tariff disruptions, revenue from the US market rose significantly in the first half of 2025 to US$8.0 million, representing a 20.0% year-on-year increase. This growth was fueled by a notable upsurge in the sales volume of coronary standard and scoring balloons and peripheral balloons during the Reporting Period, including high selling price product, Scoreflex NC balloon.

Operating Highlights

To achieve continuous success in the increasingly competitive medical device industry, we have strategically focused on enhancing OrbusNeich's brand value. This focus has clearly differentiated us from our competitors through our direct market presence, excellent sales support, commitment to innovation, and comprehensive product portfolio for PCI and PTA procedure.

Sales and marketing

OrbusNeich maintains an extensive sales network covering over 70 countries and regions through its direct sales teams and distributor network.

The Group believes that the direct sales model enhances communication between frontline personnel and healthcare professionals, thereby strengthening sales support while gathering valuable clinical insights that inspire product innovation. In the first half of 2025, the acquisition of a Taiwan-based distributor successfully transitioned the Taiwan market from a distributor model to a direct sales model. This expansion brings the total number of direct sales teams to 13 markets, including the Mainland of China, France, Germany, Hong Kong, Indonesia, Japan, Macau, Malaysia, Monaco, Singapore, Spain, Switzerland, and Taiwan, further solidifying the Group's global market influence. As of June 30, 2025, it had a total of 286 sales and marketing personnel (as of December 31, 2024: 266) and 309 distributors (as of December 31, 2024: 329). During the Reporting Period, direct sales and distributor sales contributed approximately US$48.3 million and US$35.3 million, respectively, accounting for 57.7% and 42.3% of the Group's total revenue.

To reinforce its brand recognition, the Group is continuously enhancing the professionalism of its salesforce through comprehensive training and development programs for both direct sales teams and distributors. Multiple training initiatives have been launched in the first half of 2025 for new products including eucaLimus, SUPPORT C, and VITUS. Meanwhile, the Group organized or participated in around 48 seminars, workshops, conferences, and discussion panels worldwide during the first half of 2025, including global congresses such as EuroPCR, the DGK Annual Conference, and TCTAP, as well as two Physician Exchange Program sessions in Malaysia and Vietnam, to facilitate communication with physicians.

Third-party product collaboration

The Group's global commercialization expertise is recognized by other medical device manufacturers. Building on the successful collaboration with SonoScape Medical Corp. ("**SonoScape**") in the distribution of intravascular ultrasound ("**IVUS**") products in Hong Kong and Macau last year, the Group has entered into a sole and exclusive distribution agreement with Sonoscape to distribute its IVUS products in Singapore and Malaysia. As of June 30, 2025, the Group has extended the partnership to include four direct sales markets, namely France, Germany, Spain and Switzerland, as well as six other distributor markets in Europe.

Product development

The Group is committed to the research and development of product design, material processing, and manufacturing processes. As of June 30, 2025, it owned more than 250 granted patents and published patent applications globally across key jurisdictions worldwide, including over 41 and 90 granted patents and published patent applications in the US and PRC, respectively. Such research and development activities enable the Group to develop innovative products with demonstrable performance advantages and enhance market differentiation while broadening its product portfolio.

The Group's US clinical trial for Sapphire 3 is progressing on schedule, with patient enrollment expected to be completed in Q4 2025. This clinical study aims to support the FDA registration submission with CTO indication, which significantly differentiates the product from other conventional semi-compliant balloons on the market.

In addition, in the first half of 2025, the Group obtained CE Marks for JADE PLUS and Teleport Glide, PMDA approvals for Teleport Glide and Scoreflex QUAD, FDA approvals for the COREPASS Modular Microcatheter, and NMPA approval for the guiding catheter. As of June 30, 2025, the Group had an aggregate of over 55 approved products, including 32 PMDA approved products, 42 CE marked products, 20 FDA cleared or approved products, and 23 NMPA approved products. The Group also submitted the registration application for Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA, Sapphire NC 24, JADE PLUS, Teleport XT and Teleport Glide to the NMPA, and applications for the Vascuaid Aspiration Catheter and GCE Large Lumen to the PMDA during the first half of 2025.

The Group's robust product pipeline also includes various products currently in the design stage. For example, in the coronary space, the clinical study for the proprietary paclitaxel drug-coated balloon Sapphire PTX will commence in Japan near the end of 2025. In the peripheral space, the application for the JADE Score peripheral scoring balloon's approval is expected to be submitted to the PMDA in 2026.

Production facilities

As a multinational medical device company, OrbusNeich operates production facilities in different parts of the world, including Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany. Facilities in different locations are critical to the Group's ability to navigate the changing geopolitical landscape.

Since the acquisition of eucatech AG in late 2023, the Group has invested various resources to restore its production capabilities. During the first half of 2025, production gradually ramped up to supply products for both sales and clinical registries. Combining the production capacity in Shenzhen and Hoevelaken, the Group's aggregate annual production capacity amounted to approximately 2.1 million units of balloons and stents as of June 30, 2025.

To meet future production needs, the Group is constructing its largest R&D and manufacturing facility in Hangzhou, the PRC. Construction of the main structure was completed in August 2025 and renovation work is expected to begin in the second half of the year. The new facility is anticipated to begin operation in 2027, adding an annual production capacity of 2.4 million units.

Joint venture

During the first half of 2025, OrbusNeich P&F, a joint venture focusing on the development, manufacturing and commercialization of innovative structural heart products, continued to advance clinical trials of TricValve in the PRC. In order to accelerate patient enrollment, the number of participating sites increased from 13 at the end of 2024 to 21. Additionally, the joint venture is actively promoting TricValve's hospital access in the Greater Bay Area ("**GBA**") through the Hong Kong & Macau Registered Drugs and Medical Devices Access to GBA Program. A key milestone was achieved in July of this year with the successful implantation performed at and Sun Yat-sen Memorial Hospital, Sun Yat-sen University, marking TricValve's first commercial implantation in the Mainland of China. In addition to TricValve, OrbusNeich P&F has a comprehensive pipeline of structural heart interventional devices, including Vienna Aortic Valve, a self-expandable TAVR product; a balloon expandable aortic valve product and a transcatheter mitral valve replacement product.

Outlook

In the first half of 2025, the Group recorded exceptional revenue growth in the EMEA and APAC regions and the US market. Looking ahead, continued advancements in healthcare in emerging markets will further drive sales in the APAC region. An important growth strategy for the EMEA and APAC markets is to transition selected markets from a distributor sales model to a direct sales model, with the aim of strengthening market presence and increasing revenue. Following the acquisition of the Taiwan distributor in the first half of the year, we will expedite local product registrations to expand its portfolio. In the second half of the year, the Group plans to establish direct sales teams in Belgium and the Netherlands to further expand its direct market presence in Europe. Additionally, with the completion of clinical registration and regulatory approvals for eucaLimus, SUPPORT C and VITUS expected by year-end, these products are set to drive revenue growth for the Group.

For the Japanese market, the next-generation non-slip balloon, Scoreflex QUAD, received PMDA approval in the first half of the year and is scheduled for launch in Q4 2025. The Group expects that the superior performance and premium pricing of the product will help reverse the decline in revenue in the Japanese market. Furthermore, with additional new products, including an aspiration catheter, a dual lumen catheter and a large lumen guide catheter extension, expected to obtain PMDA approval before the end of the year, the Group believes that revenue from Japan will regain its growth momentum.

Regarding the PRC market, the Henan Provincial Medical Security Bureau recently convened a research meeting regarding the draft guidelines for the Henan Interprovincial Alliance VBP program, with implementation expected by the end of 2025. The Group will leverage its first-mover advantage of its Scoreflex scoring balloon to actively participate in this VBP initiative. While the expansion of VBP will inevitably lead to a short-term decline in average selling prices, participation in VBP will accelerate hospital access for the Group's products. This strategy not only enhances hospital coverage for products included in the VBP program but also facilitates the commercialization of other portfolio products. In the first half of the year, the increased sales volume of Sapphire balloons, microcatheters, and guide catheter extensions in the PRC market underscored the effectiveness of this strategy. The Group will continue to diversify its product portfolio in the PRC market and has submitted registration applications to NMPA for products such as Scoreflex TRIO, Sapphire ULTRA, Sapphire NC ULTRA and JADE PLUS.

For the US market, as China-US trade negotiations show signs of progress, the tariffs levied on the Group's exports to the United States have been reduced from a peak of 145% to the current 30%. The Group will work closely with its US distributor, Abbott Laboratories, to capitalize on this favorable opportunity and expedite shipments to the US market. We are optimistic that the US market will maintain robust growth throughout the year. To more effectively address the impact of potential long-term tariffs, the Group will further leverage its advantage of possessing diversified production facilities in multiple locations. We will register products from different origins with the relevant regulatory authorities to ensure that our supply chain maintains sufficient resilience to navigate potential trade barriers.

To complement these efforts, we implement a key growth strategy that focuses on diversifying the product portfolio to drive revenue growth and achieve economies of scale. Regarding our strategic collaboration with SonoScape, the Group is working on the local product registration process and executing marketing initiatives. This partnership is positioned to generate additional revenue for the Group in the medium term. In the future, the Group will continue to actively pursue strategic collaborations, particularly with Chinese peers with strong internationalization ambitions, by capitalizing on our extensive global footprint, high brand value, and seasoned overseas sales teams.

Overall, the Group is optimistic about its prospects thanks to the easing of tariff disputes, strong growth in emerging markets, the commercialization of new proprietary products, and third-party product collaborations. Furthermore, our strong financial position, with cash and bank balances of approximately US$237.1 million as of June 30, 2025, provides ample liquidity to fund potential acquisitions and the construction of new manufacturing facilities. In light of the solid financial position and in celebration of the Group's 25th anniversary, the Board has resolved to declare a special dividend of HK15 cents per ordinary share in cash, demonstrating the Group's commitment to creating value for its Shareholders.

FINANCIAL REVIEW

REVENUE

By business line

	For the six months ended June 30,			
	2025	2024	**Change**	
	US$'000	*US$'000*	*US$'000*	*%*
Coronary interventional medical devices				
Scoring balloons	**28,607**	27,312	1,295	4.7%
Non-compliant balloons	**17,919**	16,915	1,004	5.9%
Semi-compliant balloons	**17,003**	15,619	1,384	8.9%
Stents	**5,495**	5,644	(149)	–2.6%
Peripheral interventional medical devices				
Balloons	**7,198**	6,127	1,071	17.5%
Other medical devices	**2,688**	3,444	(756)	–22.0%
Third-party products	**4,640**	3,849	791	20.6%
Total	**83,550**	78,910	4,640	5.9%

Our revenue increased by US$4.6 million from US$78.9 million for the six months ended June 30, 2024 to US$83.6 million for the six months ended June 30, 2025, primarily due to (i) a US$1.3 million increase in revenue generated from our scoring balloon products as result of the increase in sales volume of our Scoreflex TRIO scoring balloons in certain APAC and EMEA direct sales countries such as Singapore, Malaysia, Germany and Switzerland, offset by the decrease in sales volume in Japan; (ii) a US$1.0 million increase in revenue generated from our non-compliant balloon products as a result of the increase in sales volume of our Sapphire NC 24 coronary balloons in certain APAC and EMEA countries such as Malaysia, France and Germany, as well as the US market; (iii) a US$1.4 million increase in revenue generated from our semi-compliant balloon products due to the increase in sales volume of Sapphire 3 coronary balloons in certain APAC and EMEA direct sales countries such as Malaysia, Indonesia, Spain, France and Germany, offset by the decrease in sales volume of Sapphire II PRO coronary balloons in certain EMEA countries such as Germany, South Africa and Saudi Arabia; (iv) a US$1.1 million increase in revenue generated from our peripheral balloon products, primarily due to the increase in sales volume of our JADE OTW peripheral balloons in the US market; (v) a US$0.8 million increase in revenue generated from the sales of third-party products, primarily due to the increase in sales volume of guidewires and guiding catheters in the Indonesia market; offset by, (vi) a US$0.8 million decrease in revenue generated from the sales of other medical devices, primarily due to the decrease in sales volume of Teleport microcatheters and non-sterilized OEM balloon catheters; and (vii) a US$0.1 million decrease in revenue generated from our coronary stents, primarily due to the net effect of (a) decrease in sales volume and average selling price of our COMBO Plus coronary stents as a result of reduction in reimbursement price since the second half of 2024 in the Japan market and (b) increase in sales volume in the Indonesia market.

By geographical area

	For the six months ended June 30,			
	2025	2024	**Change**	
	US$'000	*US$'000*	*US$'000*	*%*
APAC	**27,311**	23,955	3,356	14.0%
EMEA	**22,429**	19,170	3,259	17.0%
Japan	**16,114**	18,908	(2,794)	−14.8%
The PRC	**9,652**	10,176	(524)	−5.1%
United States	**8,044**	6,701	1,343	20.0%
Total	**83,550**	78,910	4,640	5.9%

Our revenue increased by US$4.6 million from US$78.9 million for the six months ended June 30, 2024 to US$83.6 million for the six months ended June 30, 2025, primarily due to (i) a US$3.4 million increase in revenue generated from the APAC market, as a result of (a) increase in sales volume of COMBO Plus coronary stents, Scoreflex NC scoring balloons, as well as the increase in sales volume of third-party products in Indonesia; (b) increase in sales volume of Sapphire 3 and Sapphire NC 24 coronary balloons in the Malaysia market; and (c) increase in sales volume of Scoreflex TRIO scoring balloons in the Singapore and Malaysia markets; (ii) a US$3.2 million increase in revenue generated from the EMEA market, primarily due to (a) an increase in sales volume of Sapphire 3, Sapphire NC 24 coronary balloons and Scoreflex TRIO scoring balloons in the Germany, Spain and France markets; and (b) an increase in sales volume of Scoreflex NC scoring balloons and Sapphire II NC coronary balloons in the United Kingdom market; (iii) a US$1.3 million increase in revenue generated from the US market, primarily due to an increase in sales volume of Scoreflex NC scoring balloons and JADE OTW peripheral balloons, offset by, (iv) a US$2.8 million decrease in revenue generated from the Japan market, mainly due to (a) decrease in sales volume of Scoreflex TRIO scoring balloons since there was a new cutting balloon launched by our competitor in late 2024; and (b) decrease in average selling prices of our COMBO Plus coronary stents as a result of the reduction in reimbursement price since the second half of 2024; and (v) a US$0.5 million decrease in revenue generated from the PRC market, primarily due to the decrease in average selling price our Scoreflex scoring balloons as compared to the same period of 2024, after being included in Beijing-Tianjin-Hebei "3+N" Alliance volume-based procurement scheme since the second half of 2024 and the depreciation of Renminbi against US dollars.

Cost of sales

Cost of sales increased by 19.5% from US$23.1 million for the six months ended June 30, 2024 to US$27.7 million for the six months ended June 30, 2025, primarily due to the overall increase in sales volume.

Gross profit and gross profit margin

Gross profit for the six months ended June 30, 2025 and 2024 was US$55.9 million and US$55.8 million, respectively. Gross profit margin for the six months ended June 30, 2025 and 2024 were 66.9% and 70.7%, respectively. The decrease in gross profit margin was primarily due to (i) decrease in average selling prices in the PRC and Japan markets; (ii) decrease in sales volume in the Japan market, where the product selling prices were higher than the Group average; and (iii) increase in sales volume in Indonesia market, where the product selling prices were lower as compared to other markets.

Other income — net

Other income decreased by 30.8% from US$0.2 million for the six months ended June 30, 2024 to US$0.1 million for the six months ended June 30, 2025, primarily due to the decrease in government grant to support our R&D projects in the PRC.

Other gains/(losses) — net

We recorded US$1.1 million of net gains for the six months ended June 30, 2025, as compared to US$0.9 million of net losses for the six months ended June 30, 2024, mainly due to the increase in net foreign exchange gains arising from the appreciation of Euro against US dollars.

Selling and distribution expenses

Selling and distribution expenses increased by 6.1% from US$18.5 million for the six months ended June 30, 2024 to US$19.6 million for the six months ended June 30, 2025, mainly due to (i) the increase in employee benefit expenses due to (a) reclassification of certain salary expenses previously recorded under general and administrative expenses to selling and marketing expenses according to the functions of respective teams; (b) overall salary increment of the Group; (c) the expansion of sales team for the APAC and US markets; and (d) the increase in headcount as a result of the acquisition of the Taiwan distributor in March 2025; and (ii) the increase in travelling and entertainment expenses and delivery and warehouse expenses; offset by the decrease in product evaluation service fee and commission to dealers in the Japan market.

General and administrative expenses

General and administrative expenses decreased by 6.8% from US$12.9 million for the six months ended June 30, 2024 to US$12.0 million for the six months ended June 30, 2025, primarily due to the decrease in employee benefit expenses as a result of the reclassification of certain salary expenses previously recorded under general and administrative expenses to selling and marketing expenses according to the functions of respective teams, which was partially offset by the overall salary increment of the Group.

Research and development expenses

Research and development expenses increased by 9.1% from US$7.4 million for the six months ended June 30, 2024 to US$8.1 million for the same period of 2025, primarily due to (i) the increase in service fee to contract research organizations for our pipeline products such as drug-coated balloons; and (ii) product testing fees for new generation of scoring and peripheral balloons, offset by the decrease in clinical trial expenses for our Scoreflex TRIO scoring balloons.

Finance income — net

Finance income — net decreased from US$6.1 million for the six months ended June 30, 2024 to US$4.7 million for the same period of 2025, primarily due to the decrease in interest income generated from fixed deposits as a result of the decrease in interest rate.

Share of loss of investment in a joint venture

Share of loss of investment in a joint venture increased by 21.7% from US$0.7 million for six months ended June 30, 2024 to US$0.8 million for the same period of 2025, primarily due to the decrease in revenue as a result of decrease in sales volume of TricVavle and the increase in research and development expenses during the six months ended June 30, 2025.

Income tax expense

Income tax expense decreased from US$2.4 million for the six months ended June 30, 2024 to US$0.9 million for the same period of 2025, primarily due to the recognition of deferred tax asset in relation to the tax losses in the US and Japan subsidiaries carried forward from prior years. As a result, the effective tax rates fell from 11.3% for the six months ended June 30, 2024 to 4.5% for the same period of 2025.

Profit for the period attributable to owners of the Company

As a result of the foregoing, our profit for the period attributable to owners of the Company increased by 5.1% from US$18.8 million for six months ended June 30, 2024 to US$19.8 million for the six months ended June 30, 2025, mainly due to the increase in net foreign exchange gains and decrease in income tax expense, offset by the decrease in interest income and increase in selling and marketing expenses.

CAPITAL MANAGEMENT

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for Shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to Shareholders, return capital to Shareholders, issue new shares, utilization of banking facilities or sell assets to reduce debt.

The Group monitors capital on the basis of the debt to asset ratio. The capital structure of the Group consists of Shareholders' equity. Capital is managed so as to maximize the return to Shareholders while maintaining a capital base to allow the Group to operate effectively in the market and sustain future development of the business.

LIQUIDITY AND FINANCIAL RESOURCES

The Group mainly financed its operations with its own working capital and equity funding.

As of June 30, 2025, the Group had US$237.1 million of cash and bank balances, as compared to US$248.6 million as of December 31, 2024. Such decrease was mainly attributable to the dividend payment to the Shareholders of US$10.6 million during the Reporting Period.

The Group recorded total current assets of approximately US$363.3 million as of June 30, 2025 (December 31, 2024: US$361.5 million) and total current liabilities of approximately US$29.7 million as of June 30, 2025 (December 31, 2024: US$30.7 million). As of June 30, 2025, total current liabilities of the Group primarily included trade payables, and accruals and other payables amounting to approximately US$23.5 million (December 31, 2024: US$26.6 million). As of June 30, 2025, accruals and other payables mainly consisted of (i) accruals for employee benefit expenses of US$5.1 million, (ii) payable in relation to the construction and renovation of the Group's new manufacturing facility in Hangzhou of US$3.1 million, (iii) other tax payable of US$2.6 million, and (iv) accruals for royalty expenses of US$1.1 million.

Trade receivables in terms of debtor turnover days for the six months ended June 30, 2025 increased to 96 days (six months ended June 30, 2024: 86 days), while trade payable in terms of creditor turnover days for the six months ended June 30, 2025 decreased to 39 days (six months ended June 30, 2024: 43 days).

Current ratio (calculated by dividing the total current assets by the total current liabilities) of the Group was approximately 12.2 times as of June 30, 2025 (December 31, 2024: 11.8 times).

NET CURRENT ASSETS

The Group's net current assets as of June 30, 2025 were US$333.5 million, representing an increase of 0.8% compared to net current assets of US$330.7 million as of December 31, 2024.

FOREIGN EXCHANGE EXPOSURE

The Group is exposed to currency risk primarily from various currency exposures, primarily with respect to Japanese Yen, Indonesian Rupiah, Renminbi and Euro. Foreign exchange risk arises when future commercial transactions or recognized assets or liabilities are denominated in a currency that is not the Group's subsidiaries' functional currency, US dollar.

Our management manages the foreign exchange risks by performing regular review and monitoring our foreign exchange exposure. Our management has also set up a policy to require the subsidiaries of our Group to manage their foreign exchange risk against their functional currencies.

For the six months ended June 30, 2025, the Group recorded net foreign exchange gains of US$1.5 million (six months ended June 30, 2024: net foreign exchange losses of US$0.7 million).

CAPITAL EXPENDITURE

For the Reporting Period, the Group's total capital expenditures amounted to approximately US$11.4 million, which principally consisted of expenditures for the purchases of property, plant and equipment, intangible assets and right-of-use assets.

CHARGE ON ASSETS

As of June 30, 2025, the Group did not have any charge on assets.

TREASURY POLICY

The Directors will continue to follow the Group's prudent treasury policy to manage its financial resources, with the objective of maintaining its highly liquid position to ensure future growth opportunities would be captured when they arise.

SIGNIFICANT INVESTMENTS HELD AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Our Group's investment strategy for significant investments is to identify investment opportunities with growth potential that facilitate our expansion of product portfolio, strengthen our R&D capabilities, broaden our hospital coverage and increase our market penetration.

The Group intends to utilize the net proceeds raised from the Global Offering according to the plans set out in the section headed "Use of Proceeds from Listing" in this announcement.

There were no significant investments held with carrying amount accounting for more than 5% of the Group's total assets as of June 30, 2025, nor was there any plan authorized by the Board for other material investments or additions of capital assets as at the date of this announcement.

MATERIAL ACQUISITIONS AND DISPOSAL OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

There were no material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

CONTINGENT LIABILITIES

The Group did not have any significant contingent liabilities as of June 30, 2025.

FINANCIAL INSTRUMENTS

The Group did not have any outstanding hedge contracts or financial derivative instruments as of June 30, 2025.

EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2025, we employed 1,432 employees.

The employee benefit expense, including Directors' remuneration, was approximately US$31.0 million for the six months ended June 30, 2025, as compared to approximately US$29.0 million for the six months ended June 30, 2024. The remuneration package of employees generally includes salary and bonus elements. In general, the Group determines the remuneration package based on the qualifications, position and performance of its employees. The Group also makes contributions to statutory social insurance fund (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and childbirth insurance) and housing provident fund as applicable in the jurisdictions in which the Group operates.

The Group invests in continuing education and training programs for the management staff and other employees to upgrade their skills and knowledge continuously. It provides its employees with regular feedback as well as internal and external training in various areas, such as product knowledge, project development and team building. It also assesses the employees based on their performance to determine their salary, promotion and career development.

In addition, the Company has adopted the Pre-IPO Share Option Scheme, the Post-IPO Share Option Scheme, the Share Award Scheme A and the Share Award Scheme B. Please refer to the section headed "Share Incentive Schemes" in 2024 annual report of the Company for further details.

USE OF PROCEEDS FROM LISTING

The table below sets forth the intended application of the net proceeds and actual usage up to June 30, 2025:

Intended application	Unutilized net proceeds as of December 31, 2024 *(US$ million)*	*(%)*	Utilized net proceeds from January 1, 2025 to June 30, 2025 *(US$ million)*	Unutilized net proceeds as of June 30, 2025 *(US$ million)*	Expected timetable for the use of unutilized net proceeds
For the development and commercialization of our pipeline products					
(i) for the ongoing R&D activities for new generation of neuro interventional products; and	1.4	4.4%	—	1.4	By the end of 2025
(ii) to support the expansion of our R&D team in our Shenzhen facility	0.3	1.0%	(0.3)	—	N/A
For the expansion of our production capacities					
(i) to construct and renovate new facilities to be built on the land acquired in 2023 with area of approximately 20,000 sq.m; and	24.4	77.2%	(7.8)	16.6	By the end of 2026
(ii) to purchase new machinery and equipment for the new manufacturing site	4.2	13.3%	—	4.2	By the end of 2027
For working capital and other general corporate purposes	1.3	4.1%	(0.3)	1.0	By the end of 2027
Total	31.6	100.0%	(8.4)	23.2	

The expected timetable for utilizing the remaining proceeds is based on the best estimates of the future market conditions made by the Group. It may be subject to change based on the current and future development of market conditions.

DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025.

2025 marks the 25th anniversary of the Group. In appreciation of the long-standing support from Shareholders, the Board has resolved to declare a special dividend of HK15 cents per ordinary share in cash payable to Shareholders whose names are on the register of members of the Company as of Wednesday, September 24, 2025. Together with the final dividend of HK10 cents per ordinary share for the year ended December 31, 2024 paid on Monday, June 16, 2025, Shareholders will receive a total dividend of HK25 cents in 2025.

For the purpose of determining Shareholders who qualify for the special dividend, the register of members of the Company will be closed from Monday, September 22, 2025 to Wednesday, September 24, 2025, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for the special dividend, all transfers of shares, accompanied by the relevant share certificates, must be lodged with the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Friday, September 19, 2025 (Hong Kong Time), being the last registration date. The special dividend will be payable on or around Monday, October 6, 2025.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2025, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

COMPLIANCE WITH THE CORPORATE GOVERNANCE PRACTICES

The Company strives to maintain high standards of corporate governance to safeguard the interests of its Shareholders and to enhance corporate value and accountability.

During the Reporting Period, the Company had complied with all the applicable code provisions of the Corporate Governance Code, except as expressly described below.

Pursuant to Code Provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. David CHIEN is the Chairman and Chief Executive Officer of the Company. With extensive experience in the medical devices industry and having served in the Company since its establishment, Mr. David CHIEN is in charge of overall strategic planning and policy execution of the Group. The Board considers that vesting the roles of chairman and chief executive officer in the same person is beneficial to the management of the Group. The balance of power and authority is ensured by the operation of the Board and the senior management which comprises experienced and diverse individuals. The Board currently comprises three Executive Directors, two Non-executive Directors and three Independent Non-executive Directors, and therefore has a strong independent element in its composition.

The Company will continue to review and enhance its corporate governance practices to ensure compliance with the Corporate Governance Code.

SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the "Policy regarding Dealing in the Securities of a Listed Company by Directors, Managers and Employees" (the "**Policy**") which incorporates the Model Code as set out in Appendix C3 of the Listing Rules as its own code of conduct regarding securities transactions by the Directors and the relevant employees. Having made specific enquiry of all Directors, all of them have confirmed that they have complied with the Policy (and the Model Code) for the Reporting Period.

SUBSEQUENT EVENTS AFTER THE REPORTING PERIOD

Saved as disclosed in this announcement, there is no other important event affecting the Group since June 30, 2025 and up to the date of this announcement.

AUDIT COMMITTEE

The Audit Committee has reviewed the interim condensed consolidated financial information for the six months ended June 30, 2025, and considered that the interim condensed consolidated financial information is in compliance with the applicable accounting standards, the Listing Rules and all other applicable legal requirements.

The interim condensed consolidated financial information has been reviewed by PricewaterhouseCoopers, the Company's independent auditor, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (https://www.hkexnews.hk) and the Company (https://orbusneich.com). The 2025 interim report of the Company will be dispatched to Shareholders in due course and available on the websites above at the same time.

"APAC"	means the 17 countries/regions out of the 21 members of the Asia-Pacific Economic Cooperation (APEC) excluding the PRC, Japan, Russia and the United States
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"CE Mark"	a certification mark that indicates conformity with health, safety and environmental protection standards for products sold within the European Economic Area
"Company"	OrbusNeich Medical Group Holdings Limited, an exempted company incorporated in the Cayman Islands whose shares are listed on the Main Board of the Stock Exchange (Stock Code: 6929)
"Corporate Governance Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"CTO"	Chronic total occlusion
"Director(s)"	the director(s) of the Company or any one of them
"EMEA"	Europe, Middle East and Africa
"FDA"	the Food and Drug Administration of the United States
"Group", "our Group", "our", "we" or "us"	the Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing"	listing of the Shares on the Main Board of the Stock Exchange

"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time)
"Indonesia"	Republic of Indonesia
"Main Board"	the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the GEM of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局) (formerly known as the China National Drug Administration and the China Food and Drug Administration)
"ONM Group Ltd."	OrbusNeich Medical Group Limited (業聚醫療集團有限公司), an exempted company incorporated in the Cayman Islands on June 8, 2017, formerly known as OrbusNeich Medical Group Limited (祥豐醫療集團有限公司), an indirect wholly owned subsidiary of the Company
"OrbusNeich P&F"	OrbusNeich P+F Company Limited, a company incorporated in the British Virgin Islands on May 15, 2017, a joint venture indirectly owned as to 50% by the Company
"PCI"	percutaneous coronary intervention, a minimally invasive procedure to open narrowed coronary arteries to restore blood flow to the heart
"PMDA"	the Pharmaceuticals and Medical Devices Agency under Japan Ministry of Health, Labor and Welfare
"Post-IPO Share Option Scheme"	the share option scheme adopted by the Company on December 5, 2022 and amended on June 6, 2024
"Pre-IPO Share Option Scheme"	the share option scheme approved and adopted by ONM Group Ltd. on December 18, 2020 and assigned to the Company on September 21, 2021
"Prospectus"	the prospectus issued by the Company dated December 13, 2022

"PTA"	percutaneous transluminal angioplasty, a minimally invasive procedure to open a blocked vessel in the peripheral vasculature using a balloon catheter to restore blood flow to a limb or an organ
"R&D"	research and development
"Reporting Period"	the six-month period from January 1, 2025 to June 30, 2025
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Share Award Scheme A"	the share award scheme adopted by the Company on March 8, 2023
"Share Award Scheme B"	the share award scheme adopted by the Company on May 16, 2023
"Share Incentive Schemes"	the Pre-IPO Share Option Scheme, the Post-IPO Share Option Scheme, the Share Award Scheme A and the Share Award Scheme B
"Share(s)"	ordinary share(s) in the share capital of the Company with the nominal value of US$0.0005 each
"Shareholder(s)"	holder(s) of Share(s)
"sq.m"	square meters
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary" or "subsidiaries"	has the meaning ascribed thereto under the Listing Rules
"TAVR"	transcatheter aortic valve replacement, a minimally invasive procedure using a catheter-based technique to replace the diseased aortic valve with a new aortic valve
"The Mainland of China" or "PRC"	the People's Republic of China excluding, for the purposes of this announcement and geographical reference only and except where the context requires otherwise, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"TMVR"	transcatheter mitral valve replacement, a catheter-based technique to implant a new mitral valve in a minimally invasive procedure that does not involve open-chest surgery

"TPVR"	transcatheter pulmonary valve replacement, a catheter-based technique to implant a new pulmonary valve in a minimally invasive procedure that does not involve open-chest surgery
"U.S." or "US"	the United States of America
"US$"	United States dollar, the lawful currency of the U.S.
"%"	percent

By Order of the Board of
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 15, 2025

As of the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.